Ⓐ
PeptiBrief
Research peptide

Thymosin Beta 4

Thymosin Beta 4 is a research peptide indexed in the PeptiBrief evidence database.

Evidence confidence

Human
Not yet assessed
Trust Engine review pending.
Animal
3/5
Multiple animal studies
2 citations
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
Not yet assessed
Trust Engine review pending.

Claimed uses

Mechanisms

Safety notes

Long-term safety, validated dosing and product quality may be uncertain outside formal clinical development.

Regulation
  • Not generally licensed as a broad tissue-repair or sports-recovery treatment; product status varies by jurisdiction and formulation.
  • Not approved for general wellness or performance use unless a specific regulated product and indication exists.

References

  1. Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis · 2021
  2. Progress on the Function and Application of Thymosin β4 · 2021
  3. Thymosin β4 Promotes Dermal Healing · 2016
  4. Thymosin β4 enhances the healing of medial collateral ligament injury · 2013
  5. Thymosin beta4 accelerates wound healing · 1999
Last reviewed
12 July 2026
Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.